Myles 2004.

Methods	BUPROPION Randomized controlled trial Setting: preoperative clinic, Australia Recruitment: Smokers awaiting surgery
Participants	47 smokers expected to undergo surgery within 8‐14w 34% F, av age 45/40, 49% smoked 21‐30 CPD
Interventions	1. Bupropion 300 mg for 7w 2. Placebo Both arms: Advice at baseline, 1 phone call 2‐4 days after TQD. Low intensity
Outcomes	Abstinence at 6m (28 day PP ‐ classified as sustained) Validation CO <= 10 ppm
Notes	More drop‐outs in placebo group. Only 20 had surgery. Funding: Alfred Hospital Research Trust, Glaxo Wellcome
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Patients were randomly allocated from a table of random numbers into one of two groups: active (bupropion) or placebo (identical appearance).
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"Double‐blind," no further detail provided.
Incomplete outcome data (attrition bias) All outcomes	Low risk	17% lost to follow‐up in the bupropion group; 9% lost to follow‐up in the placebo group. "Patients lost to follow‐up were assumed to still be smoking."